What BIOFARMA Pharmaceutical does

BIOFARMA Pharmaceutical (legally Biofarma İlaç Sanayi ve Ticaret Anonim Şirketi) is a privately held Turkish generic pharmaceutical manufacturer founded in 1945 and headquartered in Sancaktepe, Istanbul. The company operates an 18,000 m2 integrated production facility with annual capacity of 76 million boxes across solid (55M), liquid (9M), semi-solid, soft gelatin capsule, and dedicated hormone production lines, all manufactured under PICS GMP, MHRA-UK, and WHO GMP/GLP standards. Its portfolio covers approximately 60 branded generic products spanning 10 therapeutic areas including systemic anti-infectives, CNS, cardiovascular, gastrointestinal, respiratory, dermatology, antidiabetic, urinary, rare disease, and hormonal products.

The business model rests on three revenue streams: (1) own-brand generic pharmaceutical sales distributed through healthcare professional and B2B pharmaceutical channels; (2) contract manufacturing (CMO) services for leading European generic manufacturers, including hormone product supply to 12 European countries; and (3) licensing and supply agreements, with 183 product licenses currently held across 31 countries spanning EU, Middle East, Africa, CIS, and Far East markets. The company runs an in-house R&D center focused on CNS, cardiovascular, genito-urinary, gastrointestinal, anti-inflammatory, antidiabetic, anti-infective, and hormonal preparations, with TUBITAK project collaborations. Strategic positioning targets a place among the top 5 generic pharmaceutical companies in the Turkish human pharmaceutical market, supported by 650+ employees and multiple ISO certifications (9001, 14001, 45001, 27001).

Go-to-market is sales-led and channel-driven: an in-house Business Development function manages in-licensing, out-licensing, co-marketing, co-development, and contract manufacturing partnerships, while international sales operate through distributor agreements, manufacturing agreements, and license and supply agreements. Products are restricted to healthcare professional channels, pricing is not publicly disclosed, and the company holds no disclosed external investors or public listing.

Name

BIOFARMA Pharmaceutical

Legal name

Biofarma İlaç Sanayi ve Ticaret Anonim Şirketi

Website

https://biofarma.com.tr

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BIOFARMA Pharmaceutical is a privately held Turkish generic pharmaceutical manufacturer founded in 1945, producing 76 million boxes annually across 10 therapeutic areas for export to 31 countries under MHRA-UK and WHO GMP standards.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceuticals
• Contract manufacturing
• Pharmaceutical manufacturing
• Therapeutic medications
• Drug development

Headquarters

HQ city

Istanbul

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D

Revenue model

1. Generic Pharmaceutical Products: Manufacturing and sale of generic pharmaceutical products across 10 therapeutic areas including cardiovascular, CNS, gastrointestinal, anti-infective, and metabolic medications
2. Contract Manufacturing (CMO): Contract manufacturing services for European leading generic manufacturers. Supplies hormone products to 12 different European countries.
3. Licensing Revenue: License and supply agreements with international distributors. 183 product licenses held in 31 countries
4. In-licensing and Out-licensing: Business development activities include in-licensing, out-licensing, co-marketing, and co-development partnerships

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Core offering

BIOFARMA Pharmaceutical manufactures and sells generic pharmaceutical products across 10 therapeutic areas including cardiovascular, CNS, gastrointestinal, anti-infective, dermatological, antidiabetic, and metabolic medications. The company also provides contract manufacturing (CMO) services for European generic manufacturers, produces hormone products supplied to 12 European countries, and engages in licensing/distribution agreements covering 183 product licenses across 31 countries.

Product overview

BIOFARMA Pharmaceutical (Biofarma İlaç Sanayi ve Ticaret Anonim Şirketi) is a Turkish pharmaceutical manufacturing company established in 1945, producing generic pharmaceutical products across multiple therapeutic areas. The company's product portfolio is extensive and organized into therapeutic categories including systemic antibacterials (Cipro, Azeltin, Laricid, Metoprim), respiratory system medications (Katarin, Gerakon Forte, Mukoral, Airlast, Leviset, Desrinal), analgesics and anti-inflammatory drugs (Geralgine K/Plus/P, Dicol, Gerofen, Motival, Esodax, Meksun, Kamfolin, Geral), urinary system medications (Piyeloseptyl, Combo, Solifas, Toreda SR), gastrointestinal drugs (Lanzedin, Panref, Famoser, Osmolak, Sokol, Gismotal, Upslack, Enfuryl), central nervous system products (Opemin, Fulsac, Tiopram, Gabaset, Lypre, Precobal, Ricus, Zyzapin, Arypez, Duopezil, Trepar, Cozymel, Fampraxa), rare disease treatments (Jidren for ADPKD, Jadirox for iron chelation, Trotrag for ITP), cardiovascular medications (Cholvast, Atervix, Desal, İsorat, Cardivex, Nipidol, Loxibin, Loxibin Plus), dermatological products (Corbinal, Fluzole, Troderm, Clobesol, Permasol), antidiabetic medications (Vildioba, Empance, Empance Met, Teglix), hormonal contraceptives (Josei emergency contraceptive), and anthelmintic medications (Andazol). The company operates from an 18,000 m2 production facility with 76 million box annual production capacity and exports to 31 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Products Portfolio Comprehensive portfolio of generic medications spanning 10 therapeutic areas including systemic antibacterials, respiratory, analgesics/anti-inflammatory, urinary, gastrointestinal, central nervous system, rare diseases, cardiovascular, dermatological, antidiabetic, hormonal, and anthelmintic medications. Products are manufactured for distribution through healthcare professional networks and international B2B pharmaceutical distribution channels.
• Contract Manufacturing Services (CMO) Contract manufacturing services for European leading generic manufacturers, including specialized hormone product manufacturing supplied to 12 different European countries. CMO partners produce licensed products using BIOFARMA's GMP-compliant facilities.
• Licensing and Supply Agreements License and supply agreements with international distributors, including in-licensing, out-licensing, co-marketing, and co-development partnerships. 183 product licenses are held across 31 countries with a target of 311 licenses within 3 years.
• Cipro Antibiotic medication containing Ciprofloxacin (Fluoroquinolone), used to treat bacterial infections. Available in 250mg, 500mg, and 750mg tablet strengths. For healthcare professional prescribing.
• Azeltin Antibiotic containing Azithromycin (Macrolide), used to treat bacterial infections. Available as tablets and pediatric suspension.
• Laricid Antibiotic containing Clarithromycin (Macrolide), used to treat bacterial infections.
• Metoprim Antibiotic containing Sulfamethoxazole + Trimethoprim (Sulfonamide and Trimethoprim combination), used to treat various bacterial infections.
• Katarin / Katarin Forte Cold and flu medication combination containing Chlorpheniramine + Oxolamine + Paracetamol, with pseudoephedrine in the Forte variant, used for symptomatic relief of cold symptoms.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Polpharma: Poland's largest pharmaceutical manufacturer and a leading European generics producer with CMO services and CIS-region exports — directly comparable to Biofarma's EU CMO business and emerging-market reach.

Direct peers

• İlko İlaç: Turkish generic pharmaceutical manufacturer with domestic manufacturing, R&D operations, and an export footprint across CIS, Middle East, and Africa — directly comparable in product mix and regional strategy to Biofarma.
• Deva Holding: Turkey-based pharmaceutical manufacturer producing generics and specialty products across similar therapeutic areas with international licensing activities; competes in the same Turkish and emerging-market channels as Biofarma.
• Abdi İbrahim: Turkey's largest domestic pharmaceutical company, manufacturing generics and branded products across similar therapeutic categories and competing head-to-head with Biofarma in the Turkish market and selected export markets.
• Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical company with manufacturing, CMO services, and a strong MENA export footprint — highly comparable to Biofarma's Middle East/Africa orientation and generic-plus-specialty mix.
• Eczacıbaşı İlaç: Turkish pharmaceutical company within the Eczacıbaşı Group, manufacturing and marketing branded generics in similar therapeutic areas to Biofarma and sharing Turkish domestic market dynamics.

Broad incumbents

• Sandoz (Novartis): Global leader in generic and biosimilar medicines with EU GMP manufacturing scale and broad licensing networks; a benchmark for Biofarma's CMO ambitions in Europe and a competitor in tender-driven generic markets.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad therapeutic coverage, global licensing, and CMO scale; competes with Biofarma across many of the same molecules and offers a benchmark for international generics distribution.
• Aurobindo Pharma: Indian-headquartered global generic manufacturer with EU GMP facilities, extensive CMO capabilities, and emerging-market distribution — comparable to Biofarma on international expansion and contract manufacturing playbooks.
• Viatris: Global generics and specialty pharmaceutical company formed from Mylan and Upjohn, with broad product portfolios and licensing networks overlapping Biofarma's CNS, cardiovascular, and anti-infective categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/biofarmailac
• Facebookfacebook.com/biofarmailac

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOFARMA Pharmaceutical